Managing Placebo Risk in Dermatology Trials

Placebo response has long challenged dermatology trials, often making it difficult to distinguish actual treatment effect from perceived improvement.

The problem is magnified in niche indications and rare diseases, where patient numbers are small and outcomes rely heavily on subjective or visible assessments.

This webinar examines why placebo rates are disproportionately high in dermatology studies and how to address them effectively.

In today’s research environment, the discussion around placebos has changed.

As regulatory transparency increases, sponsors now face not only the scientific and operational challenge of managing placebo response but also the obligation to provide apparent, compliant oversight. The EMA’s CTIS portal has broadened public access to trial data and documentation, and the FDA’s compliance letters highlight how study design and implementation are being carefully scrutinized. These changes have reshaped expectations for how sponsors document, communicate and justify their trial strategies.

This webinar bridges the scientific, operational and regulatory perspectives behind placebo response in dermatology. Attendees will gain a deeper understanding of what drives placebo variability, how to identify and mitigate risk early and how transparency is transforming accountability across the research ecosystem. From trial design and site training to documentation and regulatory interaction, this session offers practical insights for ensuring study integrity and protecting the credibility of results in an increasingly visible world.

Register for this webinar to learn how to manage placebo risk effectively in dermatology trials.

You can register for the live event and get access to the recording here: https://xtalks.com/webinars/managing-placebo-risk-in-dermatology-trials/